[A21-75] Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book
Last updated 01.09.2021
Commission awarded on 28.05.2021 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene and have an RF mutation on the second allele
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.